Post-Marketing Surveillance of Adalimumab in Korean Hidradenitis Suppurativa Patients Under the "New-Drug Re-examination
Phase of Trial: Phase IV
Latest Information Update: 07 Aug 2017
At a glance
- Drugs Adalimumab (Primary)
- Indications Hidradenitis suppurativa
- Focus Adverse reactions
- Acronyms HS rPMS
- Sponsors AbbVie
- 02 Aug 2017 Planned End Date changed from 12 Mar 2019 to 26 Jul 2019.
- 02 Aug 2017 Planned primary completion date changed from 12 Mar 2019 to 26 Jul 2019.
- 24 Mar 2017 Status changed from not yet recruiting to recruiting.